Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Valproate reproductive safety restrictions

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Pregnancy or serious valproate toxicity

Confirmed or possible pregnancy during valproate treatment, acute liver dysfunction, pancreatitis, blood dyscrasia, severe hyperammonaemic encephalopathy or overdose requires urgent specialist assessment; abrupt unsupervised cessation can also destabilise bipolar illness.

Action: Arrange same-day specialist and obstetric or acute medical advice as appropriate, assess mental and physical stability and obtain targeted blood tests. Do not issue an automatic repeat or instruct abrupt self-discontinuation; create an individual supervised plan that addresses fetal, maternal and relapse risks.

Synopsis

Apply current MHRA valproate restrictions accurately to new and existing patients, communicate maternal and paternal reproductive risks without abrupt discontinuation, and maintain specialist, laboratory and documentation safeguards throughout bipolar treatment.

  • Do not start valproate in a new patient, male or female, under 55 unless two specialists independently agree and document that no other effective or tolerated treatment exists or compelling reasons make reproductive risks inapplicable.
  • For women and girls able to have children, valproate is used only when alternatives are ineffective or not tolerated and every Pregnancy Prevention Programme condition is met.
  • Valproate is contraindicated for bipolar disorder during pregnancy; suspected pregnancy requires urgent specialist discussion, not abrupt unsupervised stopping.
  • Maternal pregnancy exposure is associated with major congenital malformation in about 11% and developmental problems in roughly 30% to 40% of exposed children.
  • For men, MHRA precautionary advice recommends effective contraception during treatment and for at least three months afterward and no sperm donation during the same period.
  • Men planning a family within the next year should receive specialist review of alternatives; possible paternal neurodevelopmental risk is based on limited observational evidence and causality is not confirmed.
  • Existing men under 55 do not require a retrospective two-specialist authorisation solely because they already take valproate, but still need current counselling and treatment review.
  • Before treatment record weight or BMI, full blood count and liver function; repeat weight, FBC and liver tests after six months and annually, and do not measure levels routinely without a specific indication.
  • Use current MHRA materials, risk-acknowledgement forms and patient card at each required review because sex, age, fertility, partner and regulatory circumstances can change.
  • Dispense valproate in the original full pack with outer-box warnings and patient information wherever required; any exceptional split-pack supply must preserve the mandated safety information.

    • Key red flags

    A missed period, positive pregnancy test or intention to become pregnant during valproate treatment requires urgent specialist contact and supervised treatment planning.

    Jaundice, persistent vomiting, abdominal pain, profound lethargy, bruising, bleeding or recurrent infection may indicate hepatic, pancreatic or haematological toxicity.

    Confusion, reduced consciousness, vomiting or neurological deterioration can reflect overdose, hyperammonaemia, hepatic dysfunction or another acute cause needing emergency assessment.

    A new valproate start in any person under 55 without the required independent two-specialist decision and documentation breaches current safety restrictions.

    Loss of access to Pregnancy Prevention Programme review, effective contraception or annual acknowledgement makes continued prescribing unsafe until urgently resolved with the specialist.

    Investigation priorities

    01
    Regulatory eligibility reviewFirst step

    Confirm age, new or existing status, indication, alternatives, reproductive context, specialist decisions and current forms.

    Management branches

    New patient under 55Apply the two-specialist exception gate

    Valproate is proposed for the first time for a male or female patient younger than 55 years.

    1. Confirm diagnosis, exact product and licence, previous effective and tolerated alternatives and why valproate is being considered now.
    2. Obtain two independent specialist decisions and documentation that no effective tolerated alternative exists or compelling reasons make reproductive risks inapplicable.
    3. Complete sex-specific acknowledgement, pregnancy-prevention or male counselling materials and baseline tests before the first prescription is supplied.

    Key medicines

    Semi-sodium valproate oral tabletsFor an adult manic episode, the product recommends 750 mg daily by mouth in two or three divided doses, increased to the lowest effective dose; the usual total is 1000 to 2000 mg daily, individualised by response.Contraindicated for bipolar disorder in pregnancy and restricted in people under 55; also avoid or seek specialist advice with liver disease, urea-cycle or mitochondrial disorders, pancreatitis risk, blood dyscrasia and major interactions.
    Open full textbook →Answer 2 questions
    Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
    Sources

    Sources and review status

    National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

    • MHRA valproate safety measures collectionCurrent central index for regulatory measures, forms, patient guides and professional resources.
    • MHRA under-55 valproate measuresTwo-specialist initiation rule and sex-specific safety materials.
    • MHRA valproate guidance for women and girlsPregnancy Prevention Programme, quantified risks and updated new-versus-existing patient distinctions.
    • MHRA valproate precautions for menPaternal evidence limitations, contraception, sperm donation and family-planning advice.
    • MHRA full-pack valproate dispensing guidanceOriginal-pack requirement, safety warnings and exceptional split-pack information duties.
    • Depakote tablets summary of product characteristicsLicensed adult mania dosing, reproductive restrictions, contraindications and organ safety.

    Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

    Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom